Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Assunta Bianco

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 18, 2025
An early feasibility study for neurological devices: The ARCTRAN studyFrancesco Bove, Giulia Di Lazzaro, Martina Petracca, et al.
Neurology|June 8, 2018
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched studyLuca Prosperini, Matteo Lucchini, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 23, 2023
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)Clara G Chisari, Assunta Bianco, Vincenzo Brescia Morra, et al.
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 27, 2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter studyFrancesco Patti, Clara Grazia Chisari, Claudio Solaro, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Journal of Neurology|November 24, 2016
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosisLuca Prosperini, Francesco Saccà, Cinzia Cordioli, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 18, 2025
An early feasibility study for neurological devices: The ARCTRAN studyFrancesco Bove, Giulia Di Lazzaro, Martina Petracca, et al.
Neurology|June 8, 2018
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched studyLuca Prosperini, Matteo Lucchini, Shalom Haggiag, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 23, 2023
Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)Clara G Chisari, Assunta Bianco, Vincenzo Brescia Morra, et al.
Therapeutic Advances in Neurological Disorders|December 31, 2025
Real-world experience with cladribine tablets in people with multiple sclerosis: effectiveness data from a multicenter Italian studyMatteo Lucchini, Giovanna Borriello, Shalom Haggiag, et al.
Neurology and Therapy|September 19, 2025
Real-World 24-Month Outcomes of Ofatumumab in Relapsing Multiple Sclerosis: Efficacy, Safety, and the Impact of FrailtyGina Ferrazzano, Roberta Fantozzi, Shalom Haggiag, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|April 27, 2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter studyFrancesco Patti, Clara Grazia Chisari, Claudio Solaro, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 15, 2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Claudio Solaro, Pasquale Annunziata, et al.
Pageof 4